Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

The Lancet Infectious Diseases

Volumn 16, Issue 6, 2016, Pages 685-697

  Manns, Michael ^a,b   Samuel, Didier ^c   Gane, Edward J ^d   Mutimer, David ^e   McCaughan, Geoff ^f   Buti, Maria ^g   Prieto, Martín ^h   Calleja, José Luis ⁱ   Peck Radosavljevic, Markus ^j   Müllhaupt, Beat ^k   Agarwal, Kosh ^l   Angus, Peter ^m   Yoshida, Eric M ⁿ   Colombo, Massimo ^o   Rizzetto, Mario ^p   Dvory Sobol, Hadas ^q   Denning, Jill ^q   Arterburn, Sarah ^q   Pang, Phillip S ^q   Brainard, Diana ^q   McHutchison, John G ^q   Dufour, Jean François ^r   Van Vlierberghe, Hans ^s   van Hoek, Bart ^t   Forns, Xavier ^u   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b German Center of Infection Research (DZIF)   (Germany)

^c HÔPITAL PAUL BROUSSE   (France)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e University of Birmingham   (United Kingdom)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^m AUSTIN HOSPITAL   (Australia)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^p UNIVERSITY OF TURIN   (Italy)

^q GILEAD SCIENCES   (United States)

^r UNIVERSITY OF BERN   (Switzerland)

^s GHENT UNIVERSITY HOSPITAL   (Belgium)

^t LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^u UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE; VIRUS RNA;

ANEMIA; ARTICLE; ATTENTION DISTURBANCE; BLURRED VISION; CHILD PUGH SCORE; CHILL; CHOLESTATIC HEPATITIS; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSPNEA; ECZEMA; EDEMA; ENDOCARDITIS; EVENING DOSAGE; FEMALE; FEVER; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HEPATORENAL SYNDROME; HUMAN; HYPERBILIRUBINEMIA; KIDNEY DYSFUNCTION; LETHARGY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPEN STUDY; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; STAPHYLOCOCCAL BACTEREMIA; STOMACH HEMORRHAGE; STOMACH VARICES; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; GENETICS; GLOBAL HEALTH; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MORTALITY; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; GLOBAL HEALTH; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 84976260348     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)00052-9     Document Type: Article

References (18)

1. 1 van der Meer, AJ, Veldt, BJ, Feld, JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
2. 2 Firpi, RJ, Clark, V, Soldevila-Pico, C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 15 (2009), 1063–1071.
3. 3 Gilead Sciences. SOVALDI prescribing information. https://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf (accessed June 11, 2015).
4. 4 European Medicines Agency. Sovaldi. Summary of opinion. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002798/WC500155435.pdf (accessed June 11, 2015).
5. 5 Curry, MP, Forns, X, Chung, RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107.
6. 6 Charlton, M, Gane, E, Manns, MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
7. 7 Forns, X, Charlton, M, Denning, J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 61 (2015), 1485–1494.
8. 8 Gilead Sciences. HARVONI prescribing information. http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf (accessed June 11, 2014).
9. 9 European Medicines Agency. Harvoni. EPAR summary for the public. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003850/WC500177997.pdf (accessed June 11, 2015).
10. 10 Bourlière, M, Bronowicki, J-P, de Ledinghen, V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 15 (2015), 397–404.
11. 11 Charlton, M, Everson, GT, Flamm, SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
12. 12 Merion, RM, Schaubel, DE, Dykstra, DM, Freeman, RB, Port, FK, Wolfe, RA, The survival benefit of liver transplantation. Am J Transplant 5 (2005), 307–313.
13. 13 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
14. 14 American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/ (accessed Jan 23, 2015).
15. 15 Deterding, K, Höner Zu Siederdissen, C, Port, K, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 42 (2015), 889–901.
16. 16 Schiff, ER, Lai, C-L, Hadziyannis, S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38 (2003), 1419–1427.
17. 17 Schiff, E, Lai, C-L, Hadziyannis, S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 13 (2007), 349–360.
18. 18 Leroy, V, Dumortier, J, Coilly, A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 13 (2015), 1993–2001.